Cytokinetics Inc 8-K Filing
Ticker: CYTK · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cytokinetics Inc (ticker: CYTK) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se).
How long is this filing?
Cytokinetics Inc's 8-K filing is 2 pages with approximately 592 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 15.3 · Accepted 2025-12-12 08:54:21
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20251212.htm (8-K) — 41KB
- 0001193125-25-316904.txt ( ) — 144KB
- cytk-20251212.xsd (EX-101.SCH) — 24KB
- cytk-20251212_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026.
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential approval of MYQORZO (aficamten) by the European Commission or any other instrumentality or regulatory agency as a treatment for obstructive hypertrophic cardiomyopathy or any other indication. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from the forward-looking statements contained in this Current Report on Form 8-K. Any forward-looking statements that Cytokinetics makes in this Current Report on Form 8-K speak only as of the date of this report. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this report.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: December 12, 2025 By: /s/ John O. Faurescu John O. Faurescu SVP, Deputy General Counsel & Secretary